Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | Developments in biomarkers for neurodegeneration in RBD

Aleksandar Videnovic, MD, from the Massachusetts General Hospital, Harvard Medical School Boston, MA, outlines commonly utilized biomarkers in REM sleep behavior disorder (RBD) and highlights recent developments in detecting a diverse range of biomarkers in tissue and biofluids such as CSF and mucosal tissue. He also discusses the need for further research into the detection of blood biomarkers for neurodegeneration, which would enable mass screening for the risk of neurodegeneration within a population. Dr Videnovic also emphasizes the variety of imaging biomarkers under investigation, particularly those used to visualize dopaminergic dysfunction, which appear clinically significant for predicting phenoconversion. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.